Loading...

Ovoca Bio plc

OVB.LLSE
Healthcare
Biotechnology
£1.15
£-0.13(-9.80%)

Ovoca Bio plc (OVB.L) Stock Overview

Explore Ovoca Bio plc’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for OVB.LStats details for OVB.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for OVB.LAnalyst Recommendations details for OVB.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. It is developing BP-101, a medicinal treatment for premenopausal women with hypoactive sexual desire disorder, which is in phase II clinical study in Australia and New Zealand, and in phase III clinical trials in Russia. It also engages in mineral exploration, as well as provides support services. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018. Ovoca Bio plc was incorporated in 1985 and is based in Dublin, Ireland.

CEO

Mr. Timothy Rand McCutcheon

Employees

5

Headquarters

17 Pembroke Street Upper, Dublin

Founded

2000

Frequently Asked Questions